Presenter Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery University of Pittsburgh School of Medicine Director, Lung Cancer Section Division of Hematology/OncologyUPMC Cancer Centers Co-Director, UPMC Lung Cancer Center of Excellence Co-Director, Lung and Thoracic Malignancies Program Pittsburgh, PA
Additional Content Development Faculty Hossein Borghaei, DO ( Course Director) Director, Thoracic Medical Oncology Director, Lung Cancer Risk Assessment Fox Chase Cancer Center Philadelphia, PA
Thomas Stinchcombe, MD Associate Professor Department of Hematology/Oncology University of North Carolina Chapel Hill, NC
Heather Wakelee, MD Associate Professor Department of Medicine Division of Oncology Stanford University Stanford Clinical Cancer Center Stanford, CA
AMA PRA Category 1 Credit TM Medium
THIS PROGRAM WAS ORIGINALLY PRESENTED AS A VISITING FACULTY GRAND ROUNDS SERIES THROUGHOUT THE COUNTRY, BEGINNING ON AUGUST 12, 2014. IF YOU HAVE ALREADY RECEIVED CREDIT FOR ATTENDING ONE OF THE LIVE MEETINGS, YOU ARE INELIGIBLE TO RECEIVE CREDIT FOR THIS ENDURING ACTIVITY.
Lung cancer is the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) is the most common lung cancer type, comprising approximately 85% of all lung cancer cases. The gap between optimal management of NSCLC and current clinical practice is widening as many clinicians involved in the care of patients with NSCLC remain unaware of new evidence regarding targeted treatment approaches and/or are unable to apply the evidence in their practices. Clinicians are not consistently differentiating NSCLC patient subpopulations based on molecular abnormalities and many clinicians are not equipped to incorporate new targeted treatment approaches and emerging investigational therapies into individualized treatment plans for patients with NSCLC.
Guidelines now recommend that all patients with adenocarcinoma be tested for the epidermal growth factor receptor (EGFR) mutations and for anaplastic lymphoma kinase (ALK) gene rearrangement. Therapies targeting the signaling pathways associated with these genes are potentially very effective in patients with these specific gene alterations. Additional biomarkers continue to be investigated, and multiple new investigational targeted therapies are at various stages of clinical development. This activity will help to address clinical practice gaps related to identifying and targeting molecular abnormalities, ultimately improving outcomes for patients.
Temple University School of Medicine and MCM Education
The activity is intended for medical, radiation, and surgical oncologists, pathologists, pulmonologists and other clinicians involved in the care of patients with NSCLC.
Upon completion of this educational activity, the participant should be able to:
List biomarkers that should be identified in patients with advanced NSCLC per current guidelines.
Explain the challenges that may arise in obtaining an adequate tissue sample for molecular testing in patients with NSCLC and strategies to overcome these challenges.
Select optimal therapeutic options based on current evidence for the treatment of NSCLC with EGFR mutations.
Select optimal therapeutic options based on current evidence for the treatment of NSCLC with ALK gene rearrangements.
Describe safety and tolerability issues with NSCLC treatments that often impact patient outcomes.
Describe new and investigational biologic targets and therapies for NSCLC.
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.
PLANNING COMMITTEE DISCLOSURE STATEMENT
Planning committee members have no financial relationships to disclose.
FACULTY DISCLOSURE STATEMENT
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Hossein Borghaei, DO
Grant/Research Support: Genentech, Inc.; Millennium Pharmaceuticals, Inc.; OSI Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc.
Consultant: Genentech, Inc.
Speakers’ Bureau: Allos Therapeutics, Inc.; Amgen Inc.; Lilly; Genentech, Inc.
Mark A. Socinski, MD
Grant/Research Support: Pfizer Inc.; Lilly; Genentech, Inc.; GlaxoSmithKline; Celgene; Synta; Merrimack
Speakers’ Bureau: Genentech, Inc.; Celgene
Thomas Stinchcombe, MD
Grant/Research Support: GlaxoSmithKline; Bristol-Myers Squibb; Genentech, Inc.; Lilly
Consultant: Celgene; Genentech, Inc.; and Lilly
Heather Wakelee, MD
Grants/Researcher Support (through Stanford): Agennix; Arqule; Astra Zeneca; Bayer; Celgene; Lilly; Exelixis; Genentech, Inc.; Novartis; Pfizer Inc.; Regeneron
Credit Provider Contact Information
School of Medicine
The Albert J. Finestone, M.D., Office for CME
3500 North Broad Street, Philadelphia, PA 19140
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Commercial Support Statements
Funded by independent educational grants from Lilly and Novartis Oncology.
Participants must view/listen to the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test online.
Review the intended audience, learning objectives, and author disclosures.
Study the educational activity.
Once completed, please proceed to the post-activity survey, and post-test.
Online, choose the best answer to each post-test question. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Copyright ©2014. Temple University School of Medicine. All rights reserved.
Presented by Temple University School of Medicine and MCM Education.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, Lilly, or Novartis Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.